(NASDAQ: LIVN) Livanova's forecast annual revenue growth rate of 5.2% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Livanova's revenue in 2024 is $1,153,545,000.On average, 3 Wall Street analysts forecast LIVN's revenue for 2024 to be $65,155,621,891, with the lowest LIVN revenue forecast at $65,000,983,543, and the highest LIVN revenue forecast at $65,394,863,496. On average, 3 Wall Street analysts forecast LIVN's revenue for 2025 to be $68,592,629,156, with the lowest LIVN revenue forecast at $68,259,935,486, and the highest LIVN revenue forecast at $69,166,398,940.
In 2026, LIVN is forecast to generate $72,562,021,832 in revenue, with the lowest revenue forecast at $71,745,503,293 and the highest revenue forecast at $73,946,914,539.